Veracyte reports Q3 EPS (41c), consensus (15c)

Reports Q3 revenue $90.1M, consensus $84.4M. In Q3, the company “grew total test volume to 32,544, an increase of 23% compared to the third quarter of 2022.” “I am pleased to share we delivered another quarter of strong revenue growth, fueled by continued demand for our Decipher Prostate and Afirma tests,” said Marc Stapley, Veracyte’s chief executive officer. “These products are serving a critical unmet need for patients dealing with prostate and thyroid cancer, indications for which we believe there remains ample opportunity to fuel outsized, long-term growth.”